Evidence map›Paper›PMID 22210568›Full record

ArticleDiabetes care2012

Nationwide study on trends in hospital admissions for major cardiovascular events and procedures among people with and without diabetes in England, 2004-2009.

Eszter P Vamos, Christopher Millett, Camille Parsons, Paul Aylin, Azeem Majeed, Alex Bottle

Registry-linked trialAbstract read
In one paragraph

Article in Diabetes care, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02428374 (Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study), which is not on this map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02428374 phase4unknown statusstarted 2015, after this paper: background citation

Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction)

Ran2015Enrolled300Registered outcomes30Posted comparisons0ConditionsMyocardial FibrosisArmsRosuvastatin plus clopidogrel, Rosuvastatin plus ticagrelor, Simvastatin plus clopidogrel, Simvastatin plus ticagrelor
Open the trial in the graph
3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Rosiglitazone improves insulin resistance but does not improve exercise capacity in individuals with impaired glucose tolerance: A randomized clinical study.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2024
    Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Are We Optimizing the Use of Dual Antiplatelet Therapy in Patients Hospitalized with Acute Myocardial Infarction?Cardiovascular revascularization medicine : including molecular interventions · 2020
    Observational
  8. Diabetes, metabolic syndrome and obesity : targets and therapy · 2020
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Using Large Diabetes Databases for Research.Journal of diabetes science and technology · 2016
    Review
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Eszter P VamosDepartment of Primary Care and Public Health, Imperial College London, London, UK. e.vamos@imperial.ac.uk
Christopher Millett
Camille Parsons
Paul Aylin
Azeem Majeed
Alex Bottle

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveIt is unclear whether people with and without diabetes equally benefitted from reductions in cardiovascular disease (CVD). We aimed to compare recent trends in hospital admission rates for angina, acute myocardial infarction (AMI), stroke, percutaneous coronary intervention (PCI), and coronary artery bypass graft (CABG) among people with and without diabetes in England. RESEARCH DESIGN AND

methodsWe identified all patients aged >16 years with cardiovascular events in England between 2004-2005 and 2009-2010 using national hospital activity data. Diabetes- and nondiabetes-specific rates were calculated for each year. To test for time trend, we fitted Poisson regression models.

resultsIn people with diabetes, admission rates for angina, AMI, and CABG decreased significantly by 5% (rate ratio 0.95 [95% CI 0.94-0.96]), 5% (0.95 [0.93-0.97]), and 3% (0.97 [0.95-0.98]) per year, respectively. Admission rates for stroke did not significantly change (0.99 [0.98-1.004]) but increased for PCI (1.01 [1.005-1.03]) in people with diabetes. People with and without diabetes experienced similar proportional changes for all outcomes, with no significant differences in trends between these groups. However, diabetes was associated with an ~3.5- to 5-fold risk of CVD events. In-hospital mortality rates declined for AMI and stroke, remained unchanged for CABG, and increased for PCI admissions in both groups.

conclusionsThis national study suggests similar changes in admissions for CVD in people with and without diabetes. Aggressive risk reduction is needed to further reduce the high absolute and relative risk of CVD still present in people with diabetes.

Indexed as

Cardiovascular DiseasesDiabetes MellitusEnglandHospitalizationHumans

Identifiers

PMID22210568
PMCPMC3263914

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.